Tokai Pharmaceuticals (NASDAQ: NVUS) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitabiliy, earnings, institutional ownership and dividends.
Volatility and Risk
Tokai Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.
Profitability
This table compares Tokai Pharmaceuticals and Anika Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tokai Pharmaceuticals | N/A | -101.88% | -87.37% |
| Anika Therapeutics | 30.44% | 14.88% | 13.78% |
Institutional & Insider Ownership
36.9% of Tokai Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.3% of Anika Therapeutics shares are owned by institutional investors. 39.9% of Tokai Pharmaceuticals shares are owned by company insiders. Comparatively, 6.6% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Tokai Pharmaceuticals and Anika Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tokai Pharmaceuticals | 0 | 2 | 0 | 0 | 2.00 |
| Anika Therapeutics | 0 | 0 | 0 | 0 | N/A |
Tokai Pharmaceuticals currently has a consensus price target of $1.15, suggesting a potential downside of 70.51%. Given Tokai Pharmaceuticals’ higher probable upside, equities research analysts plainly believe Tokai Pharmaceuticals is more favorable than Anika Therapeutics.
Earnings and Valuation
This table compares Tokai Pharmaceuticals and Anika Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | EBITDA | Earnings Per Share | Price/Earnings Ratio | |
| Tokai Pharmaceuticals | N/A | N/A | -$5.09 million | ($18.09) | -0.22 |
| Anika Therapeutics | $111.36 million | 6.79 | $56.02 million | $2.26 | 22.82 |
Anika Therapeutics has higher revenue and earnings than Tokai Pharmaceuticals. Tokai Pharmaceuticals is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Anika Therapeutics beats Tokai Pharmaceuticals on 8 of the 10 factors compared between the two stocks.
About Tokai Pharmaceuticals
Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.
About Anika Therapeutics
Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.
Receive News & Ratings for Tokai Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tokai Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
